My Treatment Approach: Translating Evidence to Clinical Practice in Advanced RCC   - Episode 4

STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

,

Dr. Martin H. Voss provides an analysis of the recent data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, focusing on the phase 3 STELLAR trial, which evaluates the safety and efficacy of the combination therapy Zanzalintinib and nivolumab in patients with non-clear cell renal cell carcinoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Evolving Treatment Standards in Non-Clear Cell RCC
    EP. 2: Extended Follow Up of KEYNOTE-B61
    EP. 3: Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC
    Now Viewing
    EP. 4: STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC
    EP. 5: Case Presentation: 61-year-old male Renal Cell Carcinoma
    EP. 6: Use of Combination Regimens in Frontline RCC
    EP. 7: Treatment Decision Making in first-line combinations for advanced RCC
    EP. 8: AE Management for Combination Regimens in Advanced RCC
    EP. 9: AE Management for Combination Regimens in Advanced RCC
    EP. 10: Optimizing Treatment in Advanced RCC
    EP. 11: Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile
    EP. 12: Updates in the Treatment Approach for Non-clear cell RCC
    EP. 13: Dr Albiges Reviews Long term follow up data from KEYNOTE-B61
    EP. 14: Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC
    EP. 15: Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)
    EP. 16: Summary and Forward Looking for RCC
    1. Please discuss the recent data presented at ASCO 2024 on the phase 3 STELLAR trial
      1. Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study (Abstract TPS4611)
    x